Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer-Reference-Cited by-同舟云学术

Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer

Published:2003-03 Issue:3 Volume:14 Page:428-432
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Anelli A.,Brentani R.R.,Gadelha A.P.,Amorim de Albuquerque A.,Soares F.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/14/3/428/555474/mdg104.pdf

Reference23 articles.

1. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results;Holmes;Ann Oncol,1999

2. Sequence dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer;Holmes;J Clin Oncol,1996

3. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study;Gianni;J Clin Oncol,2000

4. Taxol (paclitaxel): mechanisms of action;Horwitz;Ann Oncol,1994

5. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells;Motwani;Clin Cancer Res,1999

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam;Oncology and Therapy;2023-06-08

2. High Expression of NRF2 and Low Expression of KEAP1 Predict Worse Survival in Patients With Operable Triple-Negative Breast Cancer;Journal of Breast Cancer;2023

3. Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk;Cancer Cell International;2022-08-19

4. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial;npj Breast Cancer;2021-11-25

5. p53 Is Not Required for High CIN to Induce Tumor Suppression;Molecular Cancer Research;2020-09-18